AAIC 2021 | Aducanumab: what’s the latest?

Stephen Salloway, MD, MS, of Warren Alpert Medical School of Brown University, Providence, RI, discusses the newly published appropriate use recommendations for aducanumab, created to guide clinicians following the FDA’s accelerated approval of aducanumab for the treatment of early Alzheimer’s disease (AD) in June 2021. The recommendations outline appropriate patient populations, contraindications, optimal dosing, symptom management, and patient-clinician communication guidance. Dr Salloway highlights the benefits of the approval of aducanumab, which will move the field forward and accelerate further drug development. He hopes for wide insurance coverage of aducanumab in the US and believes that the use of this drug will act as an incentive to diagnose AD early, rather than waiting until clinical symptoms of dementia. This interview took place during the Alzheimer’s Association International Conference (AAIC) 2021.